Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Wu, Z., Guo, Z., Gearing, M
Chiao, S
Taken together, in addition to some common benefits for CV systems, it is likely that GLP-1RAs improved overall CV outcomes mainly by reduction in atherosclerotic events, whereas SGLT2 inhibitors improved CV outcomes mainly via prevention of HF-related outcomes (Fig
More research is needed before GLP-1 drugs can be recommended for breast cancer prevention
Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis